Phenotypic and Genotypic Profile of Enterobacteriaceae Isolated at a Teaching Hospital in Ghana

Authors

Bismark Donkor[1], Faustina Halm-Lai[1], Richael Odarkor Mills[3], Philimon Mwintige[4], Alberta Bedford Moses[5], Abigail Asmah Brown[5] Oheneba Charles Kofi Hagan[2]

Affiliations

[1]Department of Microbiology and Immunology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Ghana.

[2]Department of Medical Biochemistry, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Ghana.

[3]Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Ghana.

[4]Department of Microbiology, Cape Coast Teaching Hospital, Ghana.

[5]Laboratory Department, Cape Coast Teaching Hospital, Ghana

Correspondence : bismark01d@gmail.com, ock.hagan@uccsms.ucc.edu.gh

Abstract

Background: Antibiotic resistance in *Enterobacteriaceae* continue to rise and its implications on health care delivery intensified. We investigated the genetic basis for antimicrobial resistance (AMR), virulence genes and associated plasmids in *Enterobacteriaceae* isolates at a teaching hospital in Ghana.

Materials and methods: Antimicrobial susceptibility testing was performed on archived isolates. Whole genome sequencing was performed on a subset of the isolates which were either multi-drug resistant or extend spectrum beta-lactamases (ESBL)producing. Bioinformatic analyses were performed for speciation, identification of AMR and virulence genes as well as associated plasmids.

Results: The 100 *Enterobacteriaceae* isolates included in this study expressed high phenotypic resistance to beta-lactams, and high susceptibility to aminoglycosides. The 20 WGS isolates were identified genotypically based on housekeeping genes *Escherichia coli* (8/20, 40%), *Klebsiella pneumoniae* (8/20, 40%), *Enterobacter cloacae* (2/20, 10%), and *Salmonella enterica* (1/20, 5%). These harboured 139 unique antibiotic resistant genes encoding resistance against beta-lactams (65/139), aminoglycosides (23/139), fluoroquinolones (45/139), tetracyclines (35/139), phenicols (28/139), and sulphonamides (9/139). Subsequent AST performed revealed that (74/79, 94%) were ESBL producers, and (9/79,11%) were CRE. The isolates expressed 8 main categories of virulence factors with adherence, effector delivery systems, and metabolic factors predominating in decreasing order. Additionally, 26 unique plasmid replicons of both I-complex and colicin plasmids were detected.

Conclusion: We identified marked phenotypic and genotypic evidence of antimicrobial resistance to commonly used antibiotics in the isolates at the hospital.

Keywords: *Enterobacteriaceae*, AMR, WGS, plasmids, virulence factor

Introduction

The *Enterobacteriaceae* group are widely distributed in nature, particularly in the environment and gastrointestinal tract of animal. They are Gram negative, non-spore forming, anaerobic, reduce nitrite to nitrate, and ferment glucose (Janda & Abbott, 2021; Jenkins et al., 2017; Octavia & Lan, 2014). Although majority of them are commensals, some genera have impacted on human and animal health. These include *Escherischia coli*, *Klebsiella spp*, *Citrobacter spp*, *Salmonella spp*, and *Enterobacter spp*(Janda & Abbott, 2021; Renata Silva-Lacerda et al., 2015; Tacconelli et al., 2018).

The emergence and persistence of antimicrobial resistance (AMR) in the *Enterobateriaceae* to antimicrobials of various classes especially the extended-spectrum beta-lactams (ESBLs), carbapenems and fluoroquinolones in clinical settings have hampered global healthcare delivery especially in the lower- and middle-income countries (LMICs) 2020 (Lynch et al., 2021; Walsh et al., 2023). A systematic review and meta-analysis by Bezabih et al. found an eightfold increase in global antibiotic resistance enterobacteriaceae (ARE) rate, particularly, isolates that

are ESBL carriage from 2003 to 2018 (Bezabih et al., 2022). Other observations present data that highlights the prevalence of CTM-X-15 gene, one type ESBL gene that is mostly dominant among pathogenic enterobacteriaceae (Asare et al., 2024; Irenge et al., 2019). With regards to carbapenem resistance, the pooled prevalence globally is higher compared to data available in African. They report NDM, IMP and VIM-type as the main drive of CRE, especially NDM-1. However, data present in Ghana reveals low harborage of NDM-1 (Ayibieke et al., 2018; Bachelle et al., 2024). Nonetheless, CRE in Ghana keeps on rising. Mills et al and Ayibieke et al reported that carbapenem-hydrolyzing class D β-lactamases, mainly OXA type genes are observed among enterobacteriaceae in Ghana (Ayibieke et al., 2018; Mills et al., 2024).

Aside ARGs, these bacteria harbour genes of virulence factors (VFs)**.** The VFs are important for the *Enterobacteriacea*e to successfully colonize and survive in their hosts (Bujňáková et al., 2022; Dekker et al., 2021) , and eventually cause infections (Lynch et al., 2021). VFs encompass diverse mechanisms such as host cell adhesion (eg. pili, adhesins), tissue invasion (eg. invasins, hyaluronidase), toxin production (eg. exotoxins, endotoxins), immune evasion (eg. capsules, antigenic variation), enzymes facilitating spread (eg. coagulase, proteases), iron acquisition (eg. siderophores), secretion systems (eg. Type III/VI), intracellular survival strategies, antiphagocytic(Bujňáková et al., 2022; Leitão, 2020; B. Liu et al., 2022) Surveillance of VFs among enterobacteriaceae reveals an abundance of VFs in ARE (Bujňáková et al., 2022; Leitão, 2020; Pakbin et al., 2021; Payne & Neilands, 1988)**.**

Both ARGs and VFs are harboured within bacteria chromosome and mobile elements such as plasmids, transposons and integrons (Aleshina et al., 2024; Lynch et al., 2021; Partridge, 2015; Toombs-Ruane et al., 2017). Present data reveals that they usually borne on plasmids (Carattoli et al., 2021; Hawkey et al., 2022)**,** the dominant occurring mobile genetic element in antibiotic resistant bacteria (Harris et al., 2023; Wang & Dagan, 2024). Incompatibility complex (I-complex) plasmids mostly consisting of resistance and fertility groups of plasmids are prevelance in ARE(Atala, 2020; Hawkey et al., 2022; Rozwandowicz et al., 2018)**.** IncF, IncC, IncX are reported to be the most I-complex plasmids involved in the transmission of AMR among Enterobacteriaceae (Carattoli et al., 2021; Ma et al., 2023; Yu et al., 2022). In addition to the I-complex plasmids, enterobacteriaceae also harbour colicin plasmids. These plasmids produce

bacteriocins which have been reported to inhibit other bacteria in addition to being implicated in ARGs and VFs transmission (Ghanim et al., 2023). They are usually present in *Enterobacteriaceae*, especially *E. coli* strains and *Klebsiella spp* (Atala, 2020; Ghanim et al., 2023; Marković et al., 2022).

Previous studies uncovered high record of *Enterobacteriacea*e infections in the CCTH (Anning et al., 2022; Dakorah et al., 2022); however, few data on the genetic basis of ARE, especially those that are ESBL producing is revealed at the hospital due to the poor antimicrobial resistance surveillance in Ghana. This study was undertaken to profile *Enterobacteriaceae* isolated from patients at CCTH. Through phenotypic identification and antimicrobial susceptibility testing (AST), we determined the prevalence of multidrug-resistant (MDR) strains, extended-spectrum β-lactamase (ESBL) producers, and carbapenem-resistant Enterobacteriaceae (CRE). Additionally, whole-genome sequencing (WGS) of 20 ESBL-producing isolates was performed to characterize their taxonomy, antimicrobial resistance genes (ARGs), virulence factors, and harboured plasmid replicons,

Materials and Methods

Study design and site

This was a retrospective study of archived *Enterobacteriaceae* isolates from patients attending CCTH, a tertiary-level health facility located in the Cape Coast Metropolitan area of the Central Region of Ghana. The hospital is a 400-bed capacity facility which serves as a referral centre for the Central, Western, Western East and Eastern regions of Ghana. The microbiology laboratory at the hospital routinely undertakes culture and sensitivity testing for microorganisms isolated from various specimen sources including blood, urine, abscess, stool, wound swabs, high vaginal and endocervical swabs. The specimen was received from the various departments within the hospital including Enterobacteriaceae isolates archived from 2020 – 2023 were included in this study. the out-patient's department (OPD), paediatric ward, the emergency wards, intensive care unit, and obstetrics and gynecology (O/G).

Bacterial isolates

Bacteria isolates of the *Enterobactericeae* group were retrieved from storage and they were phenotypically identified using standard biochemical testing including citrate, oxidase, indole, urease and triple sugar iron (TSI).

Antimicrobial susceptibility testing (AST)

AST was performed for the isolates using the following antimicrobial agents: (beta-lactams: ampicillin [AMP 10mcg], ceftriaxone [CTR, 30mcg], cefotaxime [CTX 30mcg], cefuroxime [CXM 30mcg], and meropenem [MRP, 10 mcg]; fluoroquinolones: ciprofloxacin [CIP 5mcg], levofloxacin [LEV 5mcg], and ofloxacin [OF 5mcg]; aminoglycosides: amikacin [AMK 30mcg], and gentamicin [GEN 10mcg]; sulphonamide: cotrimoxazole [COT 25mcg]; tetracycline [TET 30mcg]; and chloramphenicol [CHL 30mcg]. The AST was performed using the Kirby–Bauer disk diffusion method and the breakpoints were interpreted according to the Clinical and Laboratory Standard Institute (CLSI) 2020 guideline (CLSI, 2020). Briefly, pure colonies of the cultured isolates were picked from agar culture plate and inoculated into peptone broth to achieve turbidity equivalent to 0.5 McFarland standards. Using a sterile cotton bud, a swab of the bacteria suspension was streaked over the entire surface of freshly prepared Mueller Hinton agar (MHA) plate. The antibiotic discs were placed on the MHA in the plates within 15 minutes of bacteria inoculation. The plates were incubated at 37 □ for 24 hours. Subsequently, the zone of inhibition was measured using a metre rule in millimeters, and interpreted as sensitive, intermediate or resistant according to the CLSI 2020 guideline (CLSI, 2020). Based on the AST findings, we classified the isolates as either multidrug resistant (MDR)-resistance to 3 or more classes of antibiotics or ESBL producing.

ESBL producers screening

Isolates exhibiting an inhibitory zone diameter ≤27 mm upon exposure to cefotaxime (30 mcg), and ≤25 mm when tested with ceftriaxone (CTR: 30 mcg) according to the (CLSI, 2020) guide were identified as possible ESBL-producers. ESBL confirmatory test was performed (n=79) using ceftazidime (CAZ:10mcg) and ceftazidime-clavulanic acid (CAL: 40mcg). Isolates that exhibited an inhibitory zone diameter ≤17 mm upon exposure to ceftazidime (30 mcg), and ≤20 mm when tested with ceftazidime-clavulanic acid were confirmed as ESBL producers.

Whole genome sequencing (WGS)

Twenty isolates that were ESBL-producing were selected for WGS. Genomic DNA (gDNA) was extracted from the bacteria using the Quick-DNA mini prep plus kit (Zymo Research, Irvine, United States) according to the manufacturer's instructions. WGS was performed at WACCBIP NGS Laboratory (Accra, Ghana) using the Illumina MiSeq (Illumina, Inc, San Diego, USA). DNA quality and quantity were determined using Qubit 4.0 fluorometer (Thermo Fisher Scientific, Waltham, USA). Short read sequencing was performed using (2 x 250 bp) PE sequencing with the MiSeq® Reagent Kit v3 (600 cycle). For each sample, 100 ng of total DNA was used for library preparation. Sequencing libraries were prepared using the Illumina DNA Prep (Illumina) library preparation kit from the enriched DNA following the manufacturer's instructions. Using the Nextera XT Index Kit v2 (Illumina), distinct indices and Illumina sequencing adapters were attached to each individual library according to manufacturer's instruction. Subsequently, each library was purified using Agencourt AMPure XP beads (BeckmanCoulter). The Agilent 4200 Tapestation (Agilent) was then used to check the expected size distribution and quality of the library. The concentration of the libraries was measured using the Qubit 4.0 fluorometer (Life Technologies). Based on the Tapestation and Qubit results, the barcoded libraries were normalized and pooled at an equimolar concentration. The combined library was diluted to 18 pM, spiked with 5% Phix (v3), and then sequenced.

Bioinformatics analyses

Adapters and low-quality reads of (n=20) paired end (PE) reads were trimmed using Trimmomatic (0.39) (https://github.com/usadellab/Trimmomatic), setting Phred score at 33, ILLUMINACLIP: Nextera-PE. fa: 2:30:10, LEADING:3, TRAILING:3 and MINLEN:22. The PE trimmed reads (n=20) were assembled using SPAdes Genome Assembler (4.0.0) (https://github.com/ablab/spades), and quality assessment was assessed using QUAST (5.2.0) (https://github.com/ablab/quast). Multilocus sequence typing (MLST) (https://github.com/tseemann/mlst) which scans contigs against traditional PubMLST typing schemes, was performed to validate the identity of the isolates. Concurrently, each draft genome was screened for the presence of AMR genes using Abricate (https://github.com/tseemann/abricate) which host (CARD, PlasmidFinder, and VFDBS). Resistance and virulence genes were determined using CARD Alcock et al., 2020; Jia et al.,

2017) and VFDBS (Liu et al., 2022) respectively. Assembled contigs were further assessed to identify plasmid genes using PlasmidFinder (Carattoli et al., 2014) in order to understand the transmission of AMR genes within the *Enterobacteriaceae* populace at the hospital. Genes were selected based on both coverage and identity equal to or greater than a threshold of 95%.

Data Analysis

Data visualization was conducted using Python (v3.11) in Jupyter (v3.6.3) via Anaconda Navigator (v2.4.6), employing Matplotlib, pandas, and seaborn libraries. Heatmaps illustrating antibiotic susceptibility patterns and radar plots depicting virulence factor distributions among Enterobacteriaceae isolates were generated using the same libraries. Statistical analyses were performed in Jamovi (v2.3.28). Descriptive statistics summarized patient demographics and clinical characteristics, with medians and interquartile ranges calculated. Cohen's Kappa was used to evaluate interrater reliability between phenotypic, MLST, and rMLST identification methods, implemented via the ClinicoPath module in Jamovi.

Results

Socio-demographics and clinical data

The majority of bacteria isolates were contributed by patients of whom (70%) were females, with 34% and 36% being within the age category of 20-29 and 40-69 respectively. The ages ranged from 8 days to 85 years with median age of 40 years and interquartile range of 35 years. Of the 100 samples 51% and 10% were specimen referred from the outpatient department (OPD) and accident and emergency (A&E) respectively. Other departments including IICU, FSW, MSW, and O/G contributed 13% of the isolates. Majority of the isolates (44%) were obtained from urine samples.

Table 1: Demographics and clinical characteristics of isolates corresponding to patients at CCTH

Category	Sub-category	Percentage (%) n =100
Age in years	≤12 years	12.0
	13-19	2.0
	20 -39	34.0
	40- 69	37.0
	≥70	15.0
Sex	Female	70.0
	Male	30.0
Department	OPD	51.0
	Other Departments	13.0
	A/E	10.0
	FMW	8.0
	MMW	7.0
	ETAT	6.0
	PMW	5.0
Specimen Source	Urine	44.0
	Sputum	14.0
	HSV	12.0
	Wound Swab	12.0
	Other Sources	10.0
	Blood	8.0

OPD: Outpatient Department; A/E: Accident & Emergency; FMW: Female Medical Ward; MMW: Male Medical Ward; ETAT: Emergency Triage, Assessment & Treatment; PMW: Paediatric Medical Ward.

Antimicrobial susceptibility patterns

Of the hundred (100) isolates, 6% were determined to be MDR. ESBL testing was successful for 79, out of which 74, that is, 93.7% were ESBL-producing. About 93%, 69% and 63% of the 100 isolates were susceptible to amikacin, chloramphenicol and gentamicin, however, all the isolates were resistant to ampicillin (**Fig1)**. Meropenem sensitivity testing was successful for 79 of the isolates out of which 40.51% (32/79), 48.10% (38/79), 11.39% (9/79) were either susceptible, intermediate or resistant respectively: This suggests that the isolates are mostly susceptible to meropenem at the hospital.

Whole genome assembly

Computation of the total read count and quality metrics of the assemblies (**Additional File 4**) were consistent and of high-quality. Tseeman/mlst analysis predicted *E. coli* (8/20, 40%), *K. pneumoniae* (8/20, 40%), *E. cloacae* (2/20, 10%), and *S. enterica* (1/20, 5%). Additionally, (1/20, 5%) was identified as *Pseudomonas aeruginosa* which belongs to the family *Pseudomonadaceae* (**Additional file 1**). Agreement between the phenotypic and genotypic identification of the *Enterobacteriaceae* isolates, and Kappa were found to be moderate with 0.60 and 0.47 respectively. The statistical difference between the phenotypic and genotypic identification of the *Enterobacteriaceae* isolates was significant (p-value <□.001). It suggests strong evidence that the phenotypic and genotypic methods, including MLST and rMLST, do not consistently agree in their classification of bacterial isolates.

Resistome

CARD revealed 139 unique ARGs that would confer resistance to the following classes of antibiotics: beta-lactams (65/139), fluoroquinolones (45/139), aminoglycosides (23/139), phenicol (28/139), tetracycline (35/139), and sulphonamide (9/139) as shown in table 2. High diversity of ARGs were observed in *E. coli* (130/139) followed by *K. pneumoniae* (111/139), *E. cloacae* (9/139), and *S. enterica* (6/139), respectively. Isolate IDs BC82 (*E. coli*) harboured most ARGs (82/139) whereas lowest was detected in both BC76 and BC94 (*K. pneumoniae)* (4/139) each. *CTX-M-15*, an ESBL gene was the most observed ARG, detected among (13/19) isolates. Nine ARGs including *APH (3')-Ia*, *Erm (49)*, *EC-15*, *Escherichia_coli_emrE*, *golS*, *mdsC*, *MdtK*, *QnrD1*, and *SHV-80* were recorded as the lowest occurring ARGs among the isolates. Each were observed once in just a single isolate. Several variants of multidrug resistant genes (91/139) were observed in the isolates, especially in *E. coli* (65/91), followed by *K. pneumoniae* (44/91), *S. enterica* (5/91), and *E. cloacae* (1/91), respectively. They were observed to have conferred resistance, especially on 4 classes of antibiotics including beta-lactams, fluoroquinolones, tetracycline, and chloramphenicol.

Enterobacteriaceae Isolates
S
I
R
N/A

Fig1: Antibiotic susceptibility profiles (phenotype) of *Enterobacteriaceae* bacteria Isolates. The heatmap displays antibiotic susceptibility patterns across various *Enterobacteriaceae* isolates for different antibiotics. Each row represents a specific antibiotic, while each column corresponds to an isolate. The color-coding indicates the susceptibility categories: black: susceptible (S), red: intermediate resistance (I), beige: resistant (R), gray: data not available (N/A). The antibiotics tested were (beta-lactams: Ampicillin [Amp], Ceftriaxone [CTR], Cefotaxime [CTX], Ceftazidime [CAZ], Meropenem [MRP], and Cefuroxime [CXM]; Fluoroquinolones: Ciprofloxacin [CIP], Levofloxacin [LEV], and Ofloxacin [OF]; Aminoglycosides: Amikacin [AMK], and Gentamicin [GEN]; Sulphonamides: Cotrimoxazole [COT]; Tetracycline [TET]; Chloramphenicol [CHL]; and Ceftazidime-Clavulanic acid [CAL]).

Table 2: Presence of antimicrobial resistance genes (ARGs) in *Enterobacteriaceae* bacterial isolates

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
Aminoglycosides																				
AAC (3')-IId					■		■	■										■		**4**
AAC (3')-IIe									■		■	■	■	■						**5**
AAC (6')-Iy																			■	**1**
AAD (3'')-Ib						■	■	■	■			■	■							**6**
AAD (3')-VIb		■	■					■	■	■										**5**
AAD (6)-Id		■	■					■	■	■										**5**
AAC (3')-Via		■	■					■	■	■										**5**
aacA2					■						■									**2**
aadA5	■	■	■	■	■	■			■											**7**
aadA2										■	■		■	■						**4**
armA											■		■	■						**3**
AAC (6')-Ib-cr6	■	■		■		■	■	■	■		■	■	■	■						**11**
acrB	■	■	■	■	■	■	■	■	■											**9**
acrD	■	■	■	■	■	■	■	■	■											**9**
AcrE		■	■	■	■	■	■	■	■											**9**
AcrF	■	■	■	■	■	■	■	■	■											**9**
arr-3		■										■								**2**
ArnT									■	■	■	■	■	■	■					**6**
cpxA	■	■	■	■	■	■	■	■	■											**9**
Klebsiella_pneumoniae_KpnE									■	■	■	■	■	■	■					**7**
Klebsiella_pneumoniae_KpnF									■	■	■	■	■	■	■	■				**8**
Klebsiella_pneumoniae_KpnG									■	■	■	■	■	■	■					**7**
kdpE	■	■	■	■		■	■	■	■											**8**
Fluoroquinolones																				
AAC (6')-Ib-cr6	■	■		■		■	■	■	■		■	■	■	■						**11**
abeM							■	■												**2**
abeS							■	■												**2**
oqxA									■	■	■	■	■	■	■					**6**

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
oqxB									■	■	■	■	■	■	■					7
QnrB17											■	■	■	■				■		5
QnrD1																	■			1
QnrS1									■	■										2
adeF							■	■												2
adeG							■	■												2
adeH							■	■												2
adeI							■	■												2
adeJ							■	■												2
adeK							■	■												2
adeL							■	■												2
adeN							■	■												2
Acinetobacter_baumannii_AbaF							■	■												2
Acinetobacter_baumannii_AmvA							■	■												2
acrB	■	■	■	■	■	■	■	■	■											9
acrD	■	■	■	■	■	■	■	■	■											9
AcrE		■	■	■	■	■	■	■	■											9
AcrF	■	■	■	■	■	■	■	■	■											9
AcrS	■	■	■	■	■	■	■	■	■											9
bacA	■	■	■	■	■	■	■	■	■		■									10
CRP	■	■	■	■	■	■	■	■	■											9
eptA	■					■	■		■											4
ermA	■	■	■	■		■	■	■	■											8
ermB	■	■	■			■	■	■	■					■						9
ermK	■	■	■			■	■	■	■											8
ermR	■	■	■	■		■	■	■	■											8
ermY	■	■	■			■	■	■	■											7
Escherichia_coli_emrE			■																	1
Escherichia_coli_mdfA	■	■	■	■	■	■	■	■	■											9
evgA	■	■	■			■	■	■	■											7
evgS	■	■	■			■	■	■	■											7
gadX	■					■	■	■	■											5
marA	■	■	■	■	■	■	■	■	■											9
mdtA	■	■	■	■	■	■	■	■	■											9
mdtB	■	■	■	■	■	■	■	■	■											9

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
mdtC	■	■	■	■		■	■	■	■											**8**
mdtE	■	■	■	■	■	■	■	■	■											**9**
mdtF	■	■	■	■	■	■	■	■	■											**9**
mdtH	■	■	■	■	■	■	■	■	■											**9**
MdtK																			■	**1**
sdiA																			■	**1**
beta-Lactams																				
ADC-169							■	■												**2**
CMH-3	■	■																■		**1**
CMH-6	■	■											■				■			**2**
CMY-59	■	■									■									**1**
CTX-M-15	■		■	■		■	■	■	■	■	■	■	■	■				■		**13**
EC-5		■	■	■	■															**4**
EC-15						■														**1**
Escherichia_coli_ampC_beta-lactamase							■	■	■											**3**
NDM-1							■				■		■	■						**4**
OXA-1	■			■		■	■	■	■				■	■						**8**
OXA-402							■	■												**2**
OXA-58							■	■												**2**
SHV-106											■	■	■	■						**4**
SHV-80										■										**1**
SHV-187									■						■	■				**3**
TEM-1		■			■						■	■	■	■						**6**
TEM-35									■											**1**
adeI							■	■												**2**
adeJ							■	■												**2**
adeK							■	■												**2**
adeL							■	■												**2**
adeN							■	■												**2**
Acinetobacter_baumannii_AbaF							■	■												**2**
Acinetobacter_baumannii_AmvA							■	■												**2**
acrB	■	■	■	■	■	■	■	■	■											**9**
acrD	■	■	■	■	■	■	■	■	■											**9**
AcrE		■	■	■	■	■	■	■	■											**9**

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
AcrF	■	■	■	■	■	■	■	■	■											9
AcrS	■	■	■	■	■	■	■	■	■											9
bacA	■	■	■	■	■	■	■	■	■		■									10
CRP	■	■	■	■	■	■	■	■	■											9
eptA	■					■	■		■											4
Erm (49)											■									1
Escherichia_coli_ acrA	■	■	■	■	■	■	■	■	■											9
Escherichia_coli_ emrE			■																	1
Escherichia_coli_ mdfA	■	■	■	■	■	■	■	■	■											9
evgA	■	■	■			■	■	■	■											7
evgS	■	■	■			■	■	■	■											7
gadW		■	■	■																3
gadX	■					■	■	■	■											5
golS																			■	1
H-NS	■	■	■	■		■	■	■	■											8
Klebsiella_pneum oniae_KpnE									■	■	■	■	■	■	■					7
Klebsiella_pneum oniae_KpnF									■	■	■	■	■	■	■	■				8
Klebsiella_pneum oniae_KpnG									■	■	■	■	■	■	■					7
LptD									■	■	■		■	■	■					6
LpsB							■	■												2
marA	■	■	■	■	■	■	■	■	■											9
mdsA	■	■	■	■	■	■	■	■	■										■	10
mdsB	■	■	■	■	■	■	■	■	■										■	10
mdsC																			■	1
mdtB	■	■	■	■	■	■	■	■	■											9
mdtC	■	■	■	■		■	■	■	■											8
mdtE	■	■	■	■	■	■	■	■	■											9
mdtF	■	■	■	■	■	■	■	■	■											9
mdtN	■	■	■	■	■	■	■	■	■											9
mdtO	■	■	■	■	■	■	■	■	■											9
mdtP	■	■	■	■	■	■	■	■	■											9
MdtQ									■	■	■	■	■	■	■					8
OmpA									■	■	■	■	■	■	■	■				8

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
ramA													■				■	■		3
SAT-2					■															1
sdiA																			■	1
TolC	■	■	■	■	■	■	■	■	■											9
Sulphonamides																				
sul1	■		■	■		■			■	■	■	■	■	■						10
sul2	■		■	■	■			■		■	■	■	■	■						10
CRP	■	■	■	■	■	■	■	■	■											9
dfrA1	■	■			■															1
dfrA12	■	■								■	■		■	■						4
dfrA14	■	■									■		■	■				■		4
dfrA17	■	■	■	■		■			■											6
dfrA27												■								1
eptA	■	■				■	■		■											4
Chloramphenicol																				
catA1		■			■		■	■	■											5
catA4	■	■															■			1
catII_from_Escherichia_coli_K-12	■	■										■								1
floR							■	■												2
adeH							■	■												2
adeI							■	■												2
adeJ							■	■												2
adeK							■	■												2
adeN							■	■												2
Acinetobacter_baumannii_AbaF							■	■												2
Acinetobacter_baumannii_AmvA							■	■												2
acrB	■	■	■	■	■	■	■	■	■											9
acrD	■	■	■	■	■	■	■	■	■											9
AcrE		■	■	■	■	■	■	■	■											9
AcrF	■	■	■	■	■	■	■	■	■											9
FosA6									■	■	■	■	■	■	■	■				7
golS																			■	1
marA	■	■	■	■	■	■	■	■	■											9
mdsA	■	■	■	■	■	■	■	■	■										■	10
mdsB	■	■	■	■	■	■	■	■	■										■	10
mdsC																			■	1

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	BC 15	BC 18	BC 26	BC 64	BC 73	BC 81	BC 82	BC 16	BC 20	BC 37	BC 54	BC 71	BC 75	BC 76	BC 94	BC 06	BC35	BC38	
mdtG	■	■	■	■	■	■	■	■	■											9
mdtM			■	■		■	■	■	■											6
mdtN	■	■	■	■	■	■	■	■	■											9
mdtO	■	■	■	■	■	■	■	■	■											9
mdtP	■	■	■	■	■	■	■	■	■											9
MdtQ									■	■	■	■	■	■	■					8
sdiA																			■	1
Tetracyclines																				
tet(A)			■	■	■	■				■	■		■	■						8
tet(B)	■	■					■	■	■											4
tet(D)												■			■					2
tet (39)							■	■												2
adeA							■	■												2
adeB							■	■												2
adeF							■	■												2
adeG							■	■												2
adeH							■	■												2
adeI							■	■												2
adeJ							■	■												2
adeK							■	■												2
adeL							■	■												2
adeN							■	■												2
adeR							■	■												2
adeS							■	■												2
acrB	■	■	■	■	■	■	■	■	■											9
acrD	■	■	■	■	■	■	■	■	■											9
AcrE		■	■	■	■	■	■	■	■											9
AcrF	■	■	■	■	■	■	■	■	■											9
AcrS	■	■	■	■	■	■	■	■	■											9
ermA	■	■	■	■		■	■	■	■											8
ermB	■	■	■	■		■	■	■	■					■						9
ermK	■	■	■			■	■	■	■											8
ermR	■	■	■	■		■	■	■	■											8
ermY	■	■	■			■	■	■	■											7
evgA	■	■	■			■	■	■	■											7
evgS	■	■	■			■	■	■	■											7
H-NS	■	■	■	■		■	■	■	■											8
Klebsiella_pneum									■	■	■	■	■	■	■					7

ARGs	*E. coli*								*K. Pneumoniae*								*E. cloacae*		*S. enterica*	Number of Isolates
	BC 04	**BC 15**	**BC 18**	**BC 26**	**BC 64**	**BC 73**	**BC 81**	**BC 82**	**BC 16**	**BC 20**	**BC 37**	**BC 54**	**BC 71**	**BC 75**	**BC 76**	**BC 94**	**BC 06**	**BC35**	**BC38**	
oniae_acrA																				
Klebsiella_pneumoniae_KpnE																				**7**
Klebsiella_pneumoniae_KpnF																				**8**
Klebsiella_pneumoniae_KpnG																				**7**
marA																				**9**
sdiA																				**1**

The table presents the presence of various antimicrobial resistance genes (ARGs) across different isolates of *E. coli*, *K. pneumoniae*, *E. cloacae*, and *S. enterica*. Cells highlighted steel blue indicates the presence of gene in an isolate while cells with white colours indicate absence of genes. The numbers in the far-right column indicate the total number of isolates in which each gene was detected. They are categorized base on the class of drugs they conferred resistance. The colour code in the ARGs columns shows which class the genes present in the isolates conferred resistance on: Aminoglycosides [green], fluroquinolones [light green], beta-lactams [dark blue], sulphonamides [yellow], chloramphenicol [dark red], tetracycline [purple], and non-specific ARGs (multiple drug/class) [gold].

Virulome

Using the VFDBS several VFs previously described in the *Enterobacteriaceae* family (*E. coli, K. pneumoniae, E. cloacae, S. enterica*) were detected. In total, 414 unique virulence genes were detected (Additional file 3), categorized into 8 major groups and 17 subcategories, as detailed in Table 3 and Figure 2. The predominant VF categories included adhesins, invasins, effector delivery systems, exotoxins, immune evasins, nutrient and metabolic factors, biofilms, and exoenzymes. Majority of these VFs were observed in *E. coli* isolates, followed by *K. pneumoniae, E. cloacae,* and *S. enterica*. Adhesin-associated VFs, essential for bacterial attachment to host cell mucosae (Abraham et al., 1988) , were predominantly identified in *E. coli* and *K. pneumoniae*. Invasion-related VFs, which facilitate host cell penetration, were detected across all four genera. Effector delivery systems, including T2SS and T3SS, known for injecting bacterial proteins into host cells to manipulate immune signaling, cell death, and nutrient acquisition pathways(Nans et al., 2015; Pinaud et al., 2018) were also observed in all the genera principally in the *S. enterica* isolate as shown in *Fig 2*. Exotoxins particularly membrane-acting, intracellular active toxins were observed in *E. coli, K. pneumoniae*, and *E. cloacae* isolates, however, none was observed in the *S. enterica isolate*. Similarly, immune evasion VFs, including antiphagocytosis and complement evasion mechanisms, were present in all Enterobacteriaceae isolates except *E. cloacae.* Nutritional and metabolic VFs were present mostly in *E. coli* followed by *K. pneumoniae and E. cloacae*. These factors, particularly those involved in metal uptake, metabolic adaptation, and iron sequestration, are crucial for bacterial survival and proliferation in host environments (Payne & Neilands, 1988; Shealy et al., 2021). Biofilm-associated VFs, which contribute to antibiotic resistance, were confined to *E. coli and K. pneumoniae*. Meanwhile, proteases that degrade exogenous proteins, enhancing bacterial growth and metabolism(Liu et al., 2022), were uniquely observed in *E. cloacae*. Bacterial survival in host environments plays an important role in persistent infections (Grant & Hung, 2013). *Enterobacteriaceae* strains harbouring these VFs can subvert host immune defenses, leading to recurrent infections(Bujňáková et al., 2022; Folgori et al., 2021). The diversity of VFs identified in the *Enterobacteriaceae* isolates accentuate heir adaptability within host environments, enhancing their ability to evade antimicrobial defenses and establish infections.



Fig2. Virulence factor distribution among *Enterobacteriaceae* bacterial species. This radar chart illustrates the distribution of eight virulence factors (Adherence, Invasion, Effector delivery system, Exotoxin, Immune modulation, Nutritional/Metabolic factor, Biofilm, Exoenzyme) across four *Enterobacteriaceae* bacterial species: *E. coli* (green), *K. pneumoniae* (blue), *S. enterica* (orange), and *E. cloacae* (pink). Each axis represents a virulence factor, with the distance from the center showing its strength or pathogenic and AMR contribution in each species. *E. coli* stands out in Adherence and Nutritional/Metabolic factors, while *S. enterica* is strong in the Effector delivery system. The other species show varying levels of these factors, reflecting their different pathogenic profiles.

298 **Table 3:** Virulence factors and sub categories present among Enterobacteriaceae bacterial isolates

Virulence Factor Genes			
Organism	**Category**	**Subcategory**	**No. Unique VFs**
E. coli	Adherence		
		Fimbrial adhesin	77
		Non-fimbrial adhesin	2
	Invasion		9
	Effector delivery system		
		Type II secretion system (T2SS)	11
		Type V secretion system (T5SS)	2
		Type VI secretion system (T6SS)	14
	Exotoxin		
		Membrane-acting toxin	5
		Intracellularly active toxin	19
	Immune modulation		
		Antiphagocytosis	1
		Complement evasion/Serum resistance	1
		Inflammatory signaling pathway	6
	Nutritional/Metabolic factor		
		Metal uptake	44
	Biofilm		
		Biofilm formation	7
		Quorum sensing	2
K. pneumoniae	Adherence		
		Fimbrial adhesin	21
	Invasion		1
	Effector delivery system		

Virulence Factor Genes			
Organism	**Category**	**Subcategory**	**No. Unique VFs**
		Type II secretion system (T2SS)	1
		Type VII secretion system (T7SS)	21
	Exotoxin		
		Intracellularly active toxin	1
	Immune modulation		
		Complement evasion/Serum resistance	5
		Inflammatory signaling pathway	5
	Nutritional/Metabolic factor		
		Metal uptake	25
		Metabolic adaptation	1
	Biofilm		
		Biofilm formation	5
		Quorum sensing	3
S. enterica	Adherence		
		Fimbrial adhesin	19
		Non-fimbrial adhesin	1
	Invasion		1
	Effector delivery system		
		Type III secretion system (T3SS)	85
		Type VI secretion system (T6SS)	9
	Nutritional/Metabolic factor		
		Metal uptake	2
E. cloacae	Effector delivery system		
		Type VII secretion system (T7SS)	2
	Exotoxin		
		Membrane-acting toxin	2

Virulence Factor Genes			
Organism	**Category**	**Subcategory**	**No. Unique VFs**
	Immune modulation		
		Antiphagocytosis	3
	Nutritional/Metabolic factor		
		Metal uptake	10
	Exoenzyme		
		Protease	1

Plasmidome

The results from Plasmid Finder revealed a diverse array of plasmid types classified under Incompatibility (Inc) complex plasmids and Colicin (Col) plasmids as shown (table 4). The number of plasmid replicons per isolate varied significantly. *K. pneumoniae* exhibited the highest diversity of plasmids (18/26) followed by *E. coli* (9/26), and *E. cloacae* (5/26). The highest plasmid diversity was observed in isolate BC37 of *K. pneumoniae* (8/26), whereas BC82 (*E. coli*) and BC26 (*K. pneumoniae*) exhibited the lowest plasmid diversity (1/26 each). The only *S. enterica* in this collection harboured no plasmid replicon. Among the Inc plasmids which are mostly observed in *Enterobacteriaceae* as vehicles for AMR transmission (Rozwandowicz et al., 2018), IncF subgroups were the most frequently detected. *IncFIB (AP001918) _1* was the most prevalent, identified in 8 isolates, followed by *IncFIB(K)_1* and *IncFIA_1*, which were found in 7 isolates each. *IncFII_1, IncHI1B(pNDM-MAR) _1*, and *IncR_1* was detected in 3 isolates each. Plasmids such as *IncC_1, IncFII (29) _1, IncFII(pCoo)_1, IncX4_2,* and *pKPC-CAV1321_1* were found in only a single isolate each. Colicin plasmids which encode colicins (bacteriocins), proteins that kill other bacteria (Atala, 2020) were also distributed across the isolates. They are reported to contribute to the spread of antibiotic resistance and other virulence factors among uropathogenic *E. coli* strains and *Klebsiella spp* by co-integrating with other plasmids like *IncC, IncF, and IncN*, (Ares-Arroyo et al., 2021; Ghanim et al., 2023). *Col156_1* was the most frequently detected (4). *ColRNAI_1* was present in 3 isolates, while *Col (BS512) _1 and Col440I_1* was each observed in 2 isolates. The least common Colicin plasmids, found in single isolates, included *Col (KPHS6) _1, Col3M_1,* and *ColpVC_1*.

Table 4: Plasmid replicons present among Enterobacteriaceae isolates

PGs		*Escherichia coli*								*Klebsiella Pneumoniae*								*Enterobacter cloacae*		Number of Isolates
		BC 04	**BC 15**	**BC 18**	**BC 26**	**BC 64**	**BC 73**	**BC 81**	**BC 82**	**BC 16**	**BC 20**	**BC 37**	**BC 54**	**BC 71**	**BC 75**	**BC 76**	**BC 94**	**BC 06**	**BC 35**	
Incompatibility (I) complex Plasmid	*IncC_1*											■								**1**
	IncFIA (HI1)_1												■			■				**2**
	IncFIA_1	■		■	■	■	■	■		■										**7**
	IncFIB (AP001918) _1	■	■	■	■	■	■	■		■										**8**
	IncFIB(K)_1									■		■	■	■	■	■	■			**7**
	IncFIB(K)(pCAV1099-114)_1										■									**1**
	IncFIB(pKPHS1)_1											■				■				**2**
	IncFIB(pNDM-Mar)_1											■		■	■					**3**
	IncFII (29)_1		■																	**1**
	IncFII(pCoo)_1			■																**1**
	IncFII(pKP91)_1									■							■			**2**
	IncFII(pRSB107)_1			■	■	■														**3**
	IncFII_1	■								■					■					**3**
	IncHI1B(pNDM-MAR)_1											■		■	■					**3**
	IncI (Gamma)_1									■									■	**2**
	IncR_1												■				■		■	**3**
	IncX4_2							■												**1**
	pKPC-CAV1321_1													■						**1**
Colicin Plasmid	*Col (BS512)_1*					■							■							**2**
	Col (KPHS6)_1												■							**1**
	Col156_1						■	■	■	■										**4**
	Col3M_1																	■		**1**
	Col440I_1											■			■					**2**
	Col440II_1														■				■	**2**
	ColRNAI_1											■		■	■					**3**
	ColpVC_1																		■	**1**
Total PGs in isolate		**3**	**2**	**4**	**3**	**4**	**3**	**4**	**1**	**7**	**1**	**8**	**5**	**5**	**7**	**3**	**3**	**1**	**4**	*****

Discussion

Phenotypic surveillance of bacterial infection in the clinical settings complemented with genomic studies enable the elucidation of basis of diseases cause, accurate identification, transmission dynamics and AMR (Ahmed et al., 2024; Govender, 2022). Our study has highlighted the need for the adaptation of genetic surveillance to complement routine phenotypic investigations especially in accurate identification of bacteria and their resistance to antibiotics in resource-limited settings. We noticed a discordance between the phenotypic and genotypic identification of the bacterial isolates. For example, some. *E. coli* and *K. Pneumoniae* were phenotypically misidentified as *Citrobacter spp and an E. cloaca as S. enterica.* Rosenthal et al have posited that bacterial misidentification can arise from laboratory procedural errors, such as culture media contamination or use of suboptimal reagents (e.g., dried agar, expired substrates), which skew biochemical test results (Rosenthal et al., 1978). Additionally, evolutionary mutations in bacteria, driven by selective pressures like antibiotics or nutrient scarcity, can alter phenotypic changes via genetic mutations or horizontal gene transfer, thereby confounding precise taxonomic identification(Blount et al., 2020). Misidenfication of bacteria in the clinical setting could result in deleterious clinical outcomes, a phenomenon that can be forestalled by complementary genomic profiling (Heyman et al., 2025; Liang, 2020) . Additionally, genomic characterization can also reveal the genetic basis of AMRs even for drugs for which AST were not performed. Also, VFs and plasmid identities from genomic profiling could be used to predict the pathogenicity potential and transmissibility of AMRs respectively(Arber, 2000; Heyman et al., 2025).

ESBL-producing *Enterobacteriaceae* have been implicated in the outbreak of several bacteria borne diseases including food-borne diseases, nosocomial and care-home outbreaks (Tran et al., 2022; Ibrahim et al., 2023; van Bilsen et al., 2021). In our study, 93% of the previously suspected ESBL producers were confirmed as ESBL producing. Some hospital-based studies in Cape Coast, Ghana (Sampah et al., 2023), and other African countries (Asare Yeboah et al., 2024; Bezabih et al., 2022b; Fadare & Okoh, 2021) have reported similar rates of ESBL producing *Enterobacteriaceae*, especially in *E. coli* and *K. pneumoniae*. However, a lower rate of 14.6% was observed in a hospital-based study in Ontario, Canada (Hasan et al., 2023). Of these ESBL-producing isolates sequenced 19 harboured 17 individual beta-lactamase ARGs of

Ambler groups A, B C and D. beta-lactamases associated with ESBLs observed were mainly *SHV*, *TEM and CTX-M* type genes found in the Ambler group A. These variants are mostly penicillinases and cephalosporinases and tend to be resistant to clavulanate, sulbactam and tazobactam (Bush & Jacoby, 2010; Sawa et al., 2020). This could explain why the addition of clavulanate to ceftazidime did not improve the sensitivity profile during the AST. *CTX-M-15* a member of the Ambler class A was the predominant beta-lactamase ARG among the isolates accounting for 68.4% (13/19). Previous studies in Ghana have reported *CTX-M-15* prevalence of over 80% in *Enterobacteriaceae* (Eibach et al., 2016; Obeng-Nkrumah et al., 2023) , whereas (Asare Yeboah et al., 2024) reported a lower proportion of 52%. Globally, CTX-*M-15* is the most prevalent beta-lactamase ARG in *Enterobacteriaceae*, with a pooled prevalence reported at 16% which is lower than observed 74% (14/19) in our study. we also observed the presence of oxacillinases including OXA-1, OXA-58 and OXA-402 which also confer ESBL activity (Sawa et al., 2020). Generally, most of the isolates were sensitive to the carbapenems with just above 11% of the isolates (9/79) being phenotypically resistant to meropenem. However, only 2 of these resistant isolates, both *K. pneumoniae* (BC71 and BC75), were part of the whole genome sequenced isolates. These *K. pneumoniae* isolates harboured NDM-1 carbapenemase. NDM-1, an Ambler class B beta-lactamase has previously been described in *E. coli* clinical isolates and also from a hospital environment surveillance study (Acolatse et al., 2022; Ayibieke et al., 2018).

VFs are produced by pathogenic *Enterobacteriaceae* which enable them to colonize, persist, and ultimately cause infections in the host (Bujňáková et al., 2022; Leitão, 2020; B. Liu et al., 2022) . Majority of VFs identified in the WGS isolates were in the adherence, effector delivery systems and nutritional or metabolic factors families, mostly in the *E. coli* and *K. pneumoniae.* However, the only *S. enterica* harboured most of the effector delivery systems. Studies conducted in both Ghana and Slovakia (Bujňáková et al., 2022; Dekker et al., 2021) observed that the prevalence of these 3 VFs among *Enterobacteriaceae*, especially *E. coli*, *K. pneumoniae*, *E. cloacae*, and *S. enterica* were high. Other studies in Africa and some European countries also corroborate our findings (Amaretti et al., 2020; Dougnon et al., 2020; Hetsa et al., 2024; Leitão, 2020). From our study, the whole genome sequenced isolates included 11 isolates, that is 3 *K. pneumoniae* and 8 *E. coli* which were isolated from urine infections. Generally, for *Enterobacteriaceae* to be able to colonize and cause urinary tract infections depends on their ability to form biofilms and produce several VFs, especially adherence factors (P fimbriae, S fimbriae, type I fimbriae), iron

acquisition and sequestration (aerobactin and enterobactins), hemolysin and cytotoxic necrotizing factors (cnf1) (Assouma et al., 2023; Govindarajan & Kandaswamy, 2022).

Fimbriae are absolute prerequisite for urinary tract colonization and disease causation, because *Enterobacteriaceae* uses that to adhere to host cells and form protective biofilms in the urinary tract contributing to the pathogenesis and persistence of urinary tract infections (Connell et al., 1996; Hornick et al., 1991) . Incidentally, the *E. coli* and *K. pneumoniae* sequenced possessed numerous fimbrial genes including type 1, type 2 (P fimbriae), type 3 and S fimbriae. Specifically, *E. coli* harboured type I fimbriae (*fimA, B, I, D, E G, H, K, F, T, U, V*), P fimbriae (*papB, C, F, G, H, D, F, J, K, X)* and S fimbriae (*sfaD, E, F, C, G, H, S, X, Y)*. Studies in uropathogenic *Enterobacteriaceae* conducted in Benin, Romania, Mongolia, and Egypt reported these fimbrial genes as well (Assouma et al., 2023). Uropathogenic *K. pneumoniae* utilizes two main types of fimbriae for adhesion to the uroepithelium, type 1 and type III (Stahlhut et al., 2012). However, we observed type II fimbriae (*papF, papK*) in the 3 uropathogenic *K. pneumoniae* isolates in addition to type I fimbriae (*fimA, B, D, E, F, G, H, I, K*), and type III fimbriae (*mrkC, I, F, A, D, B, H, D*).

In addition to these adherence factors the *E. coli* isolates also harboured iron acquisition and sequestration genes including aerobactins (*iucA, iucB, iutA*), and enterobactins (*entA, entC, entE, entF, entS, entB*). The 3 *K. pneumoniae* also possessed an aerobactin (*iutA*.) and enterobactins (*entF, entA, entE, entC, entS*). Siderophores, such as enterobactins and aerobactins, enable uropathogenic *Enterobacteriaceae* to thrive in the host by scavenging iron from host epithelial cells (Qi & Han, 2018). According to (Moxley, 2022; Payne & Neilands, 1988), *Enterobacteriaceae* requires iron for growth and virulence. Hemolysin (*hlyC, hlyD*), and *cnf1* which the *E. coli* uses to damage cell nutrient and trigger siderophores to sequester irons from host for growth (Sung et al., 2024) were also observed among the *E. coli* isolates. Nhu et al. reports that hemolysin (*hlyC, D*) and cnf1 were found abundantly in UPEC strains, emphasizing their significance capacity to cause UTI (Nhu et al., 2019)

According to (Algarni et al., 2024; Nordmann & Poirel, 2005) most ARGs and VFs are borne on mobile genetic elements, especially plasmids and have become important for the dissemination of these factors within the *Enterobacteriaceae* family through horizontal or vertical gene

transfer. Plasmids have been reported as main vehicles for the transmission of ARGs including ESBLs and VF genes in humans and non-human settings (Algarni et al., 2024; Atala, 2020; Ma et al., 2023; Rozwandowicz et al., 2018). It has been reported that most plasmid replicons found for *Enterobacteriaceae* are I-complex (Incompatibility complex) plasmids and are mostly resistance and fertility plasmids in addition to colicinogenic plasmid (Benz et al., 2021; Carattoli et al., 2021; Rozwandowicz et al., 2018; Yu et al., 2022). In our study, the I-complex we observed most was the IncF (13/19 total Inc plasmids). *IncF* plasmids which are conjugative have been reported in *Enterobacteriaceae* isolated from humans, animal and the environment worldwide (Rozwandowicz et al., 2018; Stein et al., 2024; Wang et al., 2024). These plasmids have been reported worldwide in the dissemination of AMR genes, especially the ESBLs and particularly *CTX-M-15* (Naseer & Sundsfjord, 2011; Rozwandowicz et al., 2018; Stein et al., 2024). Unsurprisingly, *CTX-M-15* was the commonest ARG observed in our study. In our study, these complex group of plasmid replicons were observed in E. *coli and K. pneumoniae* similar to previous reports (Rozwandowicz et al., 2018; Stein et al., 2024). Other Inc plasmid replicons observed in our study included *IncC, IncH, IncI, IncR* and *IncX*.

The 8 colicins uncovered in our study including *Col (BS512) _1, Col156_1, Col (KPHS6) _1, ColRNAI_1, Col440I_1, Col440II_1, ColpVC_1* and *Col3M_1* could have been involved in the isolate's resistance to the antibiotics. Consistent with previous investigations, our study adds to the expanding body of evidence indicating that colicins facilitates AMR dissemination (Chérier et al., 2021; Daniels et al., 2023; Marković et al., 2022).

This study revealed the resistant profile and VFs of *Enterobacteriaceae* at CCTH, creating awareness of the serious threat ESBL producing *Enterobacteriaceae* portends to healthcare delivery. It has also highlighted plasmids associated with AMR genes transmission within the *Enterobacteriaceae* populace and informs the importance to using genomic data of bacteria isolates to infer diagnosis and prescriptions.

Conclusions

Our study revealed high rate of multi-drug AMR among the isolates, particularly to ESBL and narrow spectrum b-lactams. Several ARGs which confer resistance to ESBLs were abundant in

the 19 whole sequenced isolates. VFs genes serving as prerequisite for successful Enterobacteriaceae urinary tract colonization and infection were detected in the sequenced isolates. The outcome emphasizes the need to improve routine genomic surveillance to monitor antibiotic resistance trends and guide evidence-based interventions aimed at mitigating the spread of ARE in the Cape Coast Metropolis and other parts of Ghana.

Limitations

The phenotypic resistance assessment was limited to disc diffusion methods, mainly constrained by logistical limitations. Our findings potentially do not fully capture genetic assessment on the plasmids of the individual isolates due to the usage of illumina short reads which could lead to incomplete reconstructions of plasmids or misassembles. It should be noted that our study circumscribe only those *Enterobacteriaceae* isolates accessible from the bacteriology laboratory at CCTH, and with availability of Socio-demographic data. Thus, our phenotypic AMR assessment do not fully capture available *Enterobacteriaceae* isolates present at the time of this study at the hospital. Also due to funding constrains only 20 isolates out of the 100 isolates were whole genome sequenced; our findings potentially do not fully capture the AMR genotypic assessment of all the retrieved isolates.

Acknowledgements

We extend our heartfelt thanks to Dr. Oheneba Charles Kofi Hagan the provision of financial support, without which this research would not have been possible. Additionally, we recognize the invaluable contributions of the entire research team, whose dedication and expertise were essential at every stage, from the initial conceptualization and laboratory investigations to the final data analysis and manuscript preparation.

Authors Contribution

The conceptualization of the study, including the development of the research idea and design of the overall framework, was carried out by B.D., F.H., and O.C.K.H. Microbiology work, such as sample processing, culture, and phenotypic characterization, was performed by B.D., P.M., A.B.M., and A.A.B. Molecular experiments and sequencing procedures, including DNA

extraction, PCR, and library preparation, were conducted by B.D. and O.C.K.H. Bioinformatics workflow development and data analysis were undertaken by B.D. , and R.O.M. and O.C.K.H., who processed and interpreted the sequencing data. The manuscript was written and revised collaboratively by B.D., F.H.., R.O.M., and O.C.K.H., who contributed to the drafting, critical revision, and final approval of the text. The overall supervision of the project, including oversight of research activities and provision of guidance and resources, was provided by O.C.K.H. and F.H

Conflict of interests

The authors disclose that Dr. Oheneba Charles Kofi Hagan provided funds for the research. The remaining authors declare that there are no personal relationships that could have appeared to influence the work reported in this paper.

References

Abraham, S. N., Daxi, S., James B., D., & Edwin H., B. (1988). Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae. *Nature*, *336*, 682–684.

Acolatse, J. E. E., Portal, E. A. R., Boostrom, I., Akafity, G., Dakroah, M. P., Chalker, V. J., Sands, K., & Spiller, O. B. (2022). Environmental surveillance of ESBL and carbapenemase-producing gram-negative bacteria in a Ghanaian Tertiary Hospital. *Antimicrobial Resistance and Infection Control*, *11*(1). https://doi.org/10.1186/s13756-022-01090-2

Ahmed, S. K., Hussein, S., Qurbani, K., Ibrahim, R. H., Fareeq, A., Mahmood, K. A., & Mohamed, M. G. (2024). Antimicrobial resistance: impacts, challenges, and future prospects. *Journal of Medicine, Surgery, and Public Health*, *2*, 100081.

Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A. L. V., Cheng, A. A., Liu, S., Min, S. Y., Miroshnichenko, A., Tran, H. K., Werfalli, R. E., Nasir, J. A., Oloni, M., Speicher, D. J., Florescu, A., Singh, B., … McArthur, A. G. (2020). CARD 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Research*, *48*(D1), D517–D525. https://doi.org/10.1093/nar/gkz935

Aleshina, Y., Yeleussizova, A., Mendybayeva, A., Shevchenko, P., & Rychshanova, R. (2024). Prevalence and antimicrobial resistance of Enterobacteriaceae in the north of Kazakhstan. *Open Veterinary Journal*, *14*(2), 604–616. https://doi.org/10.5455/OVJ.2024.v14.i2.1

Algarni, S., Gudeta, D. D., Han, J., Nayak, R., & Foley, S. L. (2024). Genotypic analyses of IncHI2 plasmids from enteric bacteria. *Scientific Reports*, *14*(1). https://doi.org/10.1038/s41598-024-59870-2

Amaretti, A., Righini, L., Candeliere, F., Musmeci, E., Bonvicini, F., Gentilomi, G. A., Rossi, M., & Raimondi, S. (2020). Antibiotic Resistance, Virulence Factors, Phenotyping, and Genotyping of Non-Escherichia coli Enterobacterales from the Gut Microbiota of Healthy Subjects. *International Journal of Molecular Sciences*, *21*(5), 1847. https://doi.org/10.3390/ijms21051847

Anning, A. S., Baah, E., Buabeng, S. D., Baiden, B. G., Aboagye, B., Opoku, Y. K., Afutu, L. L., & Ghartey-Kwansah, G. (2022). Prevalence and antimicrobial resistance patterns of microbes isolated from individuals attending private diagnostic centre in Cape Coast Metropolis of Ghana. *Scientific Reports*, *12*(1). https://doi.org/10.1038/s41598-022-18595-w

Arber, W. (2000). Genetic variation: molecular mechanisms and impact on microbial evolution. *FEMS Microbiology Reviews*, *24*(1), 1–7. https://doi.org/10.1111/j.1574-6976.2000.tb00529.x

Ares-Arroyo, M., Rocha, E. P. C., & Gonzalez-Zorn, B. (2021). Evolution of ColE1-like plasmids across γ-Proteobacteria: From bacteriocin production to antimicrobial resistance. *PLoS Genetics*, *17*(11). https://doi.org/10.1371/journal.pgen.1009919

Asare Yeboah, E. E., Agyepong, N., Mbanga, J., Amoako, D. G., Abia, A. L. K., Ismail, A., Owusu-Ofori, A., & Essack, S. Y. (2024). Genomic characterization of multi drug resistant ESBL-producing Escherichia coli isolates from patients and patient environments in a teaching hospital in Ghana. *BMC Microbiology*, *24*(1). https://doi.org/10.1186/s12866-024-03406-1

Assouma, F. F., Sina, H., Adjobimey, T., Noumavo, A. D. P., Socohou, A., Boya, B., Dossou, A. D., Akpovo, L., Konmy, B. B. S., Mavoungou, J. F., Adjanohoun, A., & Baba-Moussa, L. (2023). Susceptibility and Virulence of Enterobacteriaceae Isolated from Urinary Tract Infections in Benin. *Microorganisms*, *11*(1). https://doi.org/10.3390/microorganisms11010213

Atala, L. M. (2020). A review article:Bacterial plasmids. *Novateur Publication*, *6*(12).

Ayibieke, A., Sato, W., Mahazu, S., Prah, I., Addow-Thompson, J., Ohashi, M., Suzuki, T., Iwanaga, S., Ablordey, A., & Saito, R. (2018). Molecular characterisation of the NDM-1encoding plasmid p2189-NDM in an Escherichia coli ST410 clinical isolate from Ghana. *PLoS ONE*, *13*(12). https://doi.org/10.1371/journal.pone.0209623

Bachelle, S. V., Bah, S. Y., Addo, R. T., Bediako-Bowan, A. A. A., Egyir, B., Tsatsu, S. E., Dzudzor, B., & Amarh, V. (2024). Genomic analysis of Enterobacteriaceae from colorectal cancer patients at a tertiary hospital in Ghana: a case-control study. *Scientific Reports*, *14*(1), 23195. https://doi.org/10.1038/s41598-024-74299-3

Benz, F., Huisman, J. S., Bakkeren, E., Herter, J. A., Stadler, T., Ackermann, M., Diard, M., Egli, A., Hall, A. R., Hardt, W.-D., & Bonhoeffer, S. (2021). Plasmid- and strain-specific factors drive variation in ESBL-plasmid spread in vitro and in vivo. *The ISME Journal*, *15*(3), 862–878. https://doi.org/10.1038/s41396-020-00819-4

Bezabih, Y. M., Bezabih, A., Dion, M., Batard, E., Teka, S., Obole, A., Dessalegn, N., Enyew, A., Roujeinikova, A., Alamneh, E., Mirkazemi, C., Peterson, G. M., & Bezabhe, W. M. (2022a). Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: A systematic review and meta-Analysis. *JAC-Antimicrobial Resistance*, *4*(3). https://doi.org/10.1093/jacamr/dlac048

Bezabih, Y. M., Bezabih, A., Dion, M., Batard, E., Teka, S., Obole, A., Dessalegn, N., Enyew, A., Roujeinikova, A., Alamneh, E., Mirkazemi, C., Peterson, G. M., & Bezabhe, W. M. (2022b). Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: A systematic review and meta-Analysis. *JAC-Antimicrobial Resistance*, *4*(3). https://doi.org/10.1093/jacamr/dlac048

Blount, Z. D., Barrick, J. E., Davidson, C. J., & Lenski, R. E. (2020). Genomic and phenotypic evolution of Escherichia coli in a novel citrate-only resource environment. *Nature*, *489*(7417), 513–518. https://doi.org/10.1038/nature11514

Bujňáková, D., Puvača, N., & Ćirković, I. (2022). Virulence Factors and Antibiotic Resistance of Enterobacterales. *Microorganisms*, *10*(8), 1588. https://doi.org/10.3390/microorganisms10081588

Bush, K., & Jacoby, G. A. (2010). Updated functional classification of β-lactamases. In *Antimicrobial Agents and Chemotherapy* (Vol. 54, Issue 3, pp. 969–976). https://doi.org/10.1128/AAC.01009-09

Carattoli, A., Villa, L., Fortini, D., & García-Fernández, A. (2021). Contemporary IncI1 plasmids involved in the transmission and spread of antimicrobial resistance in Enterobacteriaceae. In *Plasmid* (Vol. 118). Academic Press Inc. https://doi.org/10.1016/j.plasmid.2018.12.001

Carattoli, A., Zankari, E., García-Fernández, A., Voldby Larsen, M., Lund, O., Villa, L., Møller Aarestrup, F., & Hasman, H. (2014). *In Silico* Detection and Typing of Plasmids using PlasmidFinder and Plasmid Multilocus Sequence Typing. *Antimicrobial Agents and Chemotherapy*, *58*(7), 3895–3903. https://doi.org/10.1128/AAC.02412-14

Chérier, D., Patin, D., Blanot, D., Touzé, T., & Barreteau, H. (2021). *antibiotics The Biology of Colicin M and Its Orthologs*. https://doi.org/10.3390/antibiotics

CLSI. (2020). *Performance standards for antimicrobial susceptibility testing* (P. Wayne, Ed.; 30th edition M02). Clinical Laboratory Standard Institute.

570 Connell, I., Agace, W., Klemm, P., Schembri, M., Mărild, S., & Svanborg, C. (1996). Type 1 fimbrial
571 expression enhances Escherichia coli virulence for the urinary tract. *Proceedings of the National*
572 *Academy of Sciences*, *93*(18), 9827–9832.

573 Dakorah, M. P., Agyare, E., Acolatse, J. E. E., Akafity, G., Stelling, J., Chalker, V. J., Spiller, O. B., Aidoo, N. B.,
574 Kumi-Ansah, F., Azumah, D., Laryea, S., Incoom, R., & Ngyedu, E. K. (2022). Utilising cumulative
575 antibiogram data to enhance antibiotic stewardship capacity in the Cape Coast Teaching Hospital,
576 Ghana. *Antimicrobial Resistance and Infection Control*, *11*(1). https://doi.org/10.1186/s13756-022-
577 01160-5

578 Daniels A. O, Taye Temikotan, & Fadairo J. K. (2023). Colicin production, antibacterial effect and molecular
579 sequencing of Escherichia coli isolated form different sources. *Open Access Research Journal of*
580 *Science and Technology*, *9*(1), 010–020. https://doi.org/10.53022/oarjst.2023.9.1.0055

581 Dekker, D., Pankok, F., Thye, T., Taudien, S., Oppong, K., Akenten, C. W., Lamshöft, M., Jaeger, A., Kaase,
582 M., Scheithauer, S., Tanida, K., Frickmann, H., May, J., & Loderstädt, U. (2021). Clonal Clusters,
583 Molecular Resistance Mechanisms and Virulence Factors of Gram-Negative Bacteria Isolated from
584 Chronic Wounds in Ghana. *Antibiotics*, *10*(3), 339. https://doi.org/10.3390/antibiotics10030339

585 Do Tran, H., Nguyen, B. T., Tran, H. Q., & Tran, H. G. (2022). A cross-sectional study of the antibiotic
586 resistant prevalence of ESBL-producing Enterobacteriaceae in Vietnam. *Journal of Health Sciences*,
587 *12*(3), 184–188. https://doi.org/10.17532/jhsci.2022.1689

588 Dougnon, V., Assogba, P., Anago, E., Déguénon, E., Dapuliga, C., Agbankpè, J., Zin, S., Akotègnon, R.,
589 Moussa, L. B., & Bankolé, H. (2020). Enterobacteria responsible for urinary infections: A review
590 about pathogenicity, virulence factors and epidemiology. In *Journal of Applied Biology and*
591 *Biotechnology* (Vol. 8, Issue 1, pp. 117–124). Open Science Publishers LLP Inc.
592 https://doi.org/10.7324/JABB.2020.80118

593 Bibach, D., Campos, C. B., Krumkamp, R., Al-Emran, H. M., Dekker, D., Boahen, K. G., Kreuels, B., Adu-
594 Sarkodie, Y., Aepfelbacher, M., Park, S. E., Panzner, U., Marks, F., & May, J. (2016). Extended
595 spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural
596 Ghana, 2007–2012. *International Journal of Medical Microbiology*, *306*(4), 249–254.
597 https://doi.org/10.1016/j.ijmm.2016.05.006

598 Badare, F. T., & Okoh, A. I. (2021). Distribution and molecular characterization of ESBL, pAmpC β-
599 lactamases, and non-β-lactam encoding genes in Enterobacteriaceae isolated from hospital
600 wastewater in Eastern Cape Province, South Africa. *PLOS ONE*, *16*(7), e0254753.
601 https://doi.org/10.1371/journal.pone.0254753

602 Folgori, L., Di Carlo, D., Comandatore, F., Piazza, A., Witney, A. A., Bresesti, I., Hsia, Y., Laing, K., Monahan,
603 I., Bielicki, J., Alvaro, A., Zuccotti, G. V., Planche, T., Heath, P. T., & Sharland, M. (2021). Antibiotic
604 Susceptibility, Virulome, and Clinical Outcomes in European Infants with Bloodstream Infections
605 Caused by Enterobacterales. *Antibiotics*, *10*(6), 706. https://doi.org/10.3390/antibiotics10060706

606 Ghanim, A. F., Aldeewan, A. B., & Abbas, B. A. (2023). Colicins produced by Escherichia coli, a review. In
607 *Romanian Journal of Infectious Diseases* (Vol. 26, Issue 4, pp. 135–140). Amaltea Medical Publishing
608 House. https://doi.org/10.37897/RJID.2023.4.7

609 Govender, R. (2022). *The prevalence of selected emerging pathogenic species in wastewater and receiving*
610 *water bodies*.

Govindarajan, D. K., & Kandaswamy, K. (2022). Virulence factors of uropathogens and their role in host pathogen interactions. *The Cell Surface*, *8*. https://doi.org/10.1016/j.tcsw.2022.100075

Grant, S. S., & Hung, D. T. (2013). Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. In *Virulence* (Vol. 4, Issue 4, pp. 273–283). Taylor and Francis Inc. https://doi.org/10.4161/viru.23987

Harris, M., Fasolino, T., Ivankovic, D., Davis, N. J., & Brownlee, N. (2023). Genetic Factors That Contribute to Antibiotic Resistance through Intrinsic and Acquired Bacterial Genes in Urinary Tract Infections. In *Microorganisms* (Vol. 11, Issue 6). MDPI. https://doi.org/10.3390/microorganisms11061407

Hasan, M. R., Vincent, Y. M., Leto, D., & Almohri, H. (2023). Trends in the Rates of Extended-Spectrum-β-Lactamase-Producing Enterobacterales Isolated from Urine Cultures during the COVID-19 Pandemic in Ontario, Canada . *Microbiology Spectrum*, *11*(1). https://doi.org/10.1128/spectrum.03124-22

Hawkey, J., Cottingham, H., Tokolyi, A., Wick, R. R., Judd, L. M., Cerdeira, L., Garcia, D. de O., Wyres, K. L., & Holt, K. E. (2022). Linear plasmids in Klebsiella and other Enterobacteriaceae. *Microbial Genomics*, *8*(4). https://doi.org/10.1099/mgen.0.000807

Hetsa, B. A., Asante, J., Mbanga, J., K Abia, A. L., & Essack, S. Y. (2024). *Genomic Analysis of Virulent, Multidrug Resistant Klebsiella pneumoniae and Klebsiella oxytoca from Bloodstream Infections, South Africa*. https://ssrn.com/abstract=4717146

Heyman, G., Jonsson, S., Fatsis-Kavalopolous, N., Hjort, K., Nicoloff, H., Furebring, M., & Andersson, D. I. (2025). Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study. *The Lancet Microbe*. https://doi.org/10.1016/j.lanmic.2024.101010

Hornick, D. B., Allen, B. L., Horn, M. A., & Clegg, S. (1991). Fimbrial Types among Respiratory Isolates Belonging to the Family Enterobacteriaceae. In *JOURNAL OF CLINICAL MICROBIOLOGY*.

Ibrahim, D. R., Dodd, C. E. R., Stekel, D. J., Meshioye, R. T., Diggle, M., Lister, M., & Hobman, J. L. (2023). Multidrug-Resistant ESBL-Producing E. coli in Clinical Samples from the UK. *Antibiotics*, *12*(1). https://doi.org/10.3390/antibiotics12010169

Irenge, L. M., Ambroise, J., Bearzatto, B., Durant, J. F., Chirimwami, R. B., & Gala, J. L. (2019). Whole-genome sequences of multidrug-resistant Escherichia coli in South-Kivu Province, Democratic Republic of Congo: Characterization of phylogenomic changes, virulence and resistance genes. *BMC Infectious Diseases*, *19*(1). https://doi.org/10.1186/s12879-019-3763-3

Irfan, M., Almotiri, A., & AlZeyadi, Z. A. (2022). Antimicrobial Resistance and Its Drivers—A Review. In *Antibiotics* (Vol. 11, Issue 10). MDPI. https://doi.org/10.3390/antibiotics11101362

Janda, J. M., & Abbott, S. L. (2021). The Changing Face of the Family Enterobacteriaceae (Order: " Enterobacterales "): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes. *Clinical Microbiology Reviews*, *34*(2). https://doi.org/10.1128/CMR.00174-20

Jenkins, C., Rentenaar, R. J., Landraud, L., & Brisse, S. (2017). Enterobacteriaceae. In *Infectious Diseases, 2-Volume Set* (pp. 1565-1578.e2). Elsevier. https://doi.org/10.1016/B978-0-7020-6285-8.00180-5

Jia, B., Raphenya, A. R., Alcock, B., Waglechner, N., Guo, P., Tsang, K. K., Lago, B. A., Dave, B. M., Pereira, S., Sharma, A. N., Doshi, S., Courtot, M., Lo, R., Williams, L. E., Frye, J. G., Elsayegh, T., Sardar, D., Westman, E. L., Pawlowski, A. C., … McArthur, A. G. (2017). CARD 2017: expansion and model-centric

651 curation of the comprehensive antibiotic resistance database. *Nucleic Acids Research*, *45*(D1), D566–
652 D573. https://doi.org/10.1093/nar/gkw1004

653 Beitão, J. H. (2020). Microbial Virulence Factors. *International Journal of Molecular Sciences*, *21*(15), 5320.
654 https://doi.org/10.3390/ijms21155320

655 Jiang, K. (2020). *Bacterial Classifications in the Genomic Era*. https://pubmlst.org/vcholerae

656 Liu, B., Zheng, D., Zhou, S., Chen, L., & Yang, J. (2022). VFDB 2022: a general classification scheme for
657 bacterial virulence factors. *Nucleic Acids Research*, *50*(D1), D912–D917.
658 https://doi.org/10.1093/nar/gkab1107

659 Liu, Y., Fu, J., Wang, L., Zhao, Z., Wang, H., Han, S., Sun, X., & Pan, C. (2022). Isolation, identification, and
660 whole-genome sequencing of high-yield protease bacteria from Daqu of ZhangGong Laojiu. *PLoS*
661 *ONE*, *17*(4 April). https://doi.org/10.1371/journal.pone.0264677

662 Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021). Escalating antimicrobial resistance among
663 Enterobacteriaceae: focus on carbapenemases. *Expert Opinion on Pharmacotherapy*, *22*(11), 1455–
664 1473. https://doi.org/10.1080/14656566.2021.1904891

665 Ma, J., Wang, J., Yang, H., Su, M., Li, R., Bai, L., Feng, J., Huang, Y., Yang, Z., & Tang, B. (2023). IncHI1
666 plasmids mediated the tet(X4) gene spread in Enterobacteriaceae in porcine. *Frontiers in*
667 *Microbiology*, *14*. https://doi.org/10.3389/fmicb.2023.1128905

668 Marković, K. G., Grujović, M., Koraćević, M. G., Nikodijević, D. D., Milutinović, M. G., Semedo-Lemsaddek,
669 T., & Djilas, M. D. (2022a). Colicins and Microcins Produced by Enterobacteriaceae: Characterization,
670 Mode of Action, and Putative Applications. In *International Journal of Environmental Research and*
671 *Public Health* (Vol. 19, Issue 18). MDPI. https://doi.org/10.3390/ijerph191811825

672 Marković, K. G., Grujović, M., Koraćević, M. G., Nikodijević, D. D., Milutinović, M. G., Semedo-Lemsaddek,
673 T., & Djilas, M. D. (2022b). Colicins and Microcins Produced by Enterobacteriaceae: Characterization,
674 Mode of Action, and Putative Applications. In *International Journal of Environmental Research and*
675 *Public Health* (Vol. 19, Issue 18). MDPI. https://doi.org/10.3390/ijerph191811825

676 Mills, R. O., Dadzie, I., Le-Viet, T., Baker, D. J., Addy, H. P. K., Akwetey, S. A., Donkoh, I. E., Quansah, E.,
677 Semanshia, P. S., Morgan, J., Mensah, A., Adade, N. E., Ampah, E. O., Owusu, E., Mwintige, P.,
678 Amoako, E. O., Spadar, A., Holt, K. E., & Foster-Nyarko, E. (2024). Genomic diversity and
679 antimicrobial resistance in clinical Klebsiella pneumoniae isolates from tertiary hospitals in Southern
680 Ghana. *Journal of Antimicrobial Chemotherapy*, *79*(7), 1529–1539.
681 https://doi.org/10.1093/jac/dkae123

682 Moxley, R. A. (2022). Family Enterobacteriaceae. In *Veterinary Microbiology* (pp. 41–55). Wiley.
683 https://doi.org/10.1002/9781119650836.ch5

684 Nans, A., Kudryashev, M., Saibil, H. R., & Hayward, R. D. (2015). Structure of a bacterial type III secretion
685 system in contact with a host membrane in situ. *Nature Communications*, *6*(1), 10114.
686 https://doi.org/10.1038/ncomms10114

687 Naseer, U., & Sundsfjord, A. (2011). The CTX-M conundrum: Dissemination of plasmids and Escherichia
688 coli clones. *Microbial Drug Resistance*, *17*(1), 83–97. https://doi.org/10.1089/mdr.2010.0132

689 Nhu, N. T. K., Phan, M.-D., Forde, B. M., Murthy, A. M. V., Peters, K. M., Day, C. J., Poole, J., Kidd, T. J.,
690 Welch, R. A., Jennings, M. P., Ulett, G. C., Sweet, M. J., Beatson, S. A., & Schembri, M. A. (2019).

Complex Multilevel Control of Hemolysin Production by Uropathogenic Escherichia coli. *MBio*, *10*(5). https://doi.org/10.1128/mBio.02248-19

Nordmann, P., & Poirel, L. (2005). Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. In *Journal of Antimicrobial Chemotherapy* (Vol. 56, Issue 3, pp. 463–469). https://doi.org/10.1093/jac/dki245

Obeng-Nkrumah, N., Tawiah-Abrokwa, G. D., Owusu, E., Duah, F., Oduro-Mensah, D., Kwao, P., Evariste, B., & Labi, A.-K. (2023). Role of CTX-M-15 gene in spread of extended-spectrum beta-lactamases among immunocompetent patients in Ghana. *African Journal of Laboratory Medicine*, *12*(1). https://doi.org/10.4102/ajlm.v12i1.2135

Octavia, S., & Lan, R. (2014). The Family Enterobacteriaceae. In E. Rosenberg, E. F. DeLong, S. Lory, E. Stackebrandt, & F. Thompson (Eds.), *The Prokaryotes: Gammaproteobacteria* (pp. 225–286). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-38922-1_167

Pakbin, B., Brück, W. M., & Rossen, J. W. A. (2021). Virulence factors of enteric pathogenic Escherichia coli: A review. In *International Journal of Molecular Sciences* (Vol. 22, Issue 18). MDPI. https://doi.org/10.3390/ijms22189922

Partridge, S. R. (2015). Resistance mechanisms in Enterobacteriaceae. *Pathology*, *47*(3), 276–284. https://doi.org/10.1097/PAT.0000000000000237

Payne, S. M., & Neilands, I. B. (1988). Iron and Virulence in the Family Enterobacteriaceae. *CRC Critical Reviews in Microbiology*, *16*(2), 81–111. https://doi.org/10.3109/10408418809104468

Pinaud, L., Sansonetti, P. J., & Phalipon, A. (2018). Host Cell Targeting by Enteropathogenic Bacteria T3SS Effectors. *Trends in Microbiology*, *26*(4), 266–283. https://doi.org/10.1016/j.tim.2018.01.010

Qi, B., & Han, M. (2018). Microbial Siderophore Enterobactin Promotes Mitochondrial Iron Uptake and Development of the Host via Interaction with ATP Synthase. *Cell*, *175*(2), 571-582.e11. https://doi.org/10.1016/j.cell.2018.07.032

Renata Silva-Lacerda, G., dos Santos, G., Solidônio, E., Costa, M., Melo, R., de Souza, I., Silva, G., & Sena, K. (2015). *Study of the Enterobacteriaceae Group CESP (Citrobacter, Enterobacter, Serratia, Providencia, Morganella and Hafnia): A Review*. https://www.researchgate.net/publication/297730985

Rosenthal, S. L., Freundlich, L. F., & Washington, W. (1978). Laboratory Evaluation of a Multitest System for Identification of Gram-negative Organisms. *American Journal of Clinical Pathology*, *70*(6), 914–917. https://doi.org/10.1093/ajcp/70.6.914

Rozwandowicz, M., Brouwer, M. S. M., Fischer, J., Wagenaar, J. A., Gonzalez-Zorn, B., Guerra, B., Mevius, D. J., & Hordijk, J. (2018). Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*, *73*(5), 1121–1137. https://doi.org/10.1093/jac/dkx488

Sampah, J., Owusu-Frimpong, I., Aboagye, F. T., & Owusu-Ofori, A. (2023). Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana. *PLoS ONE*, *18*(10 October). https://doi.org/10.1371/journal.pone.0274156

Sawa, T., Kooguchi, K., & Moriyama, K. (2020). Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. In *Journal of Intensive Care* (Vol. 8, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s40560-020-0429-6

730 Shealy, N. G., Yoo, W., & Byndloss, M. X. (2021). Colonization resistance: metabolic warfare as a strategy
731 against pathogenic Enterobacteriaceae. *Current Opinion in Microbiology*, *64*, 82–90.
732 https://doi.org/10.1016/j.mib.2021.09.014

733 Stahlhut, S. G., Struve, C., Krogfelt, K. A., & Reisner, A. (2012). Biofilm formation of *Klebsiella pneumoniae*
734 on urethral catheters requires either type 1 or type 3 fimbriae. *FEMS Immunology & Medical*
735 *Microbiology*, *65*(2), 350–359. https://doi.org/10.1111/j.1574-695X.2012.00965.x

736 Stein, M., Brinks, E., Loop, J., Habermann, D., Cho, G.-S., & Franz, C. M. A. P. (2024). Antibiotic resistance
737 plasmids in *Enterobacteriaceae* isolated from fresh produce in northern Germany. *Microbiology*
738 *Spectrum*, *12*(11). https://doi.org/10.1128/spectrum.00361-24

739 Sung, K., Nawaz, M., Park, M., Chon, J., Khan, S. A., Alotaibi, K., & Khan, A. A. (2024). Comprehensive
740 Genomic Analysis of Uropathogenic E. coli: Virulence Factors, Antimicrobial Resistance, and Mobile
741 Genetic Elements. *Pathogens*, *13*(9). https://doi.org/10.3390/pathogens13090794

742 Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter,
743 G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M.,
744 Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., … Zorzet, A. (2018). Discovery, research, and
745 development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and
746 tuberculosis. *The Lancet Infectious Diseases*, *18*(3), 318–327. https://doi.org/10.1016/S1473-
747 3099(17)30753-3

748 Tilahun, M., Kassa, Y., Gedefie, A., & Ashagire, M. (2021). Emerging carbapenem-resistant
749 enterobacteriaceae infection, its epidemiology and novel treatment options: A review. In *Infection*
750 *and Drug Resistance* (Vol. 14, pp. 4363–4374). Dove Medical Press Ltd.
751 https://doi.org/10.2147/IDR.S337611

752 Toombs-Ruane, L., Benschop, J., Burgess, S., Priest, P., Murdoch, D., & French, N. (2017). Multidrug
753 resistant Enterobacteriaceae in New Zealand: a current perspective. *New Zealand Veterinary Journal*,
754 *65*(2), 62–70. https://doi.org/10.1080/00480169.2016.1269621

755 van Bilsen, W. P. H., van Dulm, E., Matser, A., Linde, I., van Duijnhoven, Y. T. H. P., Prins, J. M., Prins, M.,
756 Boyd, A., & van Dam, A. P. (2021). High carriage of ESBL-producing Enterobacteriaceae associated
757 with sexual activity among men who have sex with men. *International Journal of Antimicrobial*
758 *Agents*, *57*(3). https://doi.org/10.1016/j.ijantimicag.2021.106276

759 Walsh, T. R., Gales, A. C., Laxminarayan, R., & Dodd, P. C. (2023). Antimicrobial Resistance: Addressing a
760 Global Threat to Humanity. In *PLoS Medicine* (Vol. 20, Issue 7). Public Library of Science.
761 https://doi.org/10.1371/journal.pmed.1004264

762 Wang, X., Zhang, H., Yu, S., Li, D., Gillings, M. R., Ren, H., Mao, D., Guo, J., & Luo, Y. (2024). Inter-plasmid
763 transfer of antibiotic resistance genes accelerates antibiotic resistance in bacterial pathogens. *ISME*
764 *Journal*, *18*(1). https://doi.org/10.1093/ismejo/wrad032

765 Wang, Y., & Dagan, T. (2024). The evolution of antibiotic resistance islands occurs within the framework of
766 plasmid lineages. *Nature Communications*, *15*(1). https://doi.org/10.1038/s41467-024-48352-8

767 Yu, L., Wang, D., Li, P., Cai, Y., Zhang, X., Luo, X., Wang, P., & Mu, K. (2022). Epidemiology, molecular
768 characterization, and drug resistance of IncHI5 plasmids from Enterobacteriaceae. *International*
769 *Microbiology*, *26*(2), 371–378. https://doi.org/10.1007/s10123-022-00299-w

770